[COX-2 inhibitors and other non-steroidal anti-inflammatory agents--what is their future?].
The story of the development, approval, marketing and use of COX-2 inhibitors is one of failures at all levels. Publications in top medical journals essential for marketing were seriously flawed; many cases of thromboses in trials with rofecoxib were not revealed; trials were not representative for the population of patients; the U.S. FDA did not require the relevant trials; and the marketing was extremely aggressive and misleading. These drugs have likely caused the deaths of thousands of patients. The use of all NSAIDs should be restricted as much as possible. Drug trials should be a public enterprise.
Gøtzsche
Peter C
PC
Afdeling 7112, H:S Rigshospitalet, Det Nordiske Cochrane Center, København Ø. pcg@cochrane.dk
D000329:Advertising; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D010506:Periodicals as Topic; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors